Blood Glucose Test Strips Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Thick Film Electrochemical Films, Thin Film Electrochemical Films, Optical Strips), By End-User (Hospitals, Ambulatory Surgical Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 8.46 Billion
CAGR (2026-2031)	7.31%
Fastest Growing Segment	Gestational Diabetes
Largest Market	North America
Market Size (2031)	USD 12.92 Billion

Market Overview

The Global Blood Glucose Test Strips Market will grow from USD 8.46 Billion in 2025 to USD 12.92 Billion by 2031 at a 7.31% CAGR. Blood glucose test strips are diagnostic consumables containing reagents that react with blood samples to measure sugar levels via a glucometer. The market growth is primarily driven by the escalating global burden of diabetes and a rising geriatric population requiring chronic care. According to the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes globally. This vast patient base sustains high demand as self-monitoring becomes essential for preventing complications and maintaining glycemic control in home healthcare settings.

The market encounters a significant challenge from the increasing preference for Continuous Glucose Monitoring systems which eliminate the need for frequent painful fingersticks. This technological substitution threatens the sales volume of traditional strips as patients transition toward sensor devices offering real-time data. Consequently, the rapid proliferation of these advanced alternatives could impede the revenue expansion of conventional testing products despite the growing overall prevalence of the disease.

Key Market Drivers

The Escalating Global Prevalence of Diabetes Mellitus acts as the primary catalyst for the market, necessitating frequent and accessible glucose monitoring solutions to manage this chronic condition effectively. As the patient pool expands, particularly with the rising incidence of Type 2 diabetes due to urbanization and lifestyle changes, the volume of diagnostic testing required to maintain glycemic control increases proportionally. A substantial portion of this growth stems from the identification of previously unknown cases, which immediately converts individuals into consumers of testing supplies. According to the International Diabetes Federation, April 2025, in the 'IDF Diabetes Atlas 11th Edition', nearly 252 million adults living with diabetes globally are currently undiagnosed, representing a massive latent segment for the test strip market as screening programs intensify.

Simultaneously, the Increasing Adoption of Home-Based Self-Monitoring is reshaping patient engagement and sustaining demand for diagnostic consumables. The shift toward preventive healthcare encourages patients to actively track their blood sugar levels outside clinical settings, reducing the risk of acute complications and long-term hospitalizations. This trend is reinforced by the availability of user-friendly testing devices that facilitate regular checks, thereby driving the recurring purchase of test strips. The market's resilience and the growing emphasis on personal health management are evident in the financial performance of key industry players. According to Roche, January 2025, in the 'Annual Report 2024', the Diagnostics Division's base business achieved a sales increase of 8%, underscoring the sustained demand for diagnostic solutions. Furthermore, the overall economic burden highlights the critical need for cost-effective management tools; according to the International Diabetes Federation, in 2025, diabetes was responsible for an estimated USD 1.015 trillion in global health expenditure.

Download Free Sample Report

Key Market Challenges

The rapid proliferation of Continuous Glucose Monitoring (CGM) systems constitutes a formidable barrier to the expansion of the traditional blood glucose test strips market. Unlike conventional glucometers that require individual test strips for every reading, CGM devices utilize subcutaneous sensors to provide real-time, 24-hour glucose tracking. This technological shift fundamentally alters the consumption model for diagnostic supplies; patients utilizing sensors no longer rely on strips for routine monitoring, relegating them to occasional calibration or backup use. As the reliance on frequent finger-prick testing diminishes, the recurring sales volume of consumable strips—the primary revenue generator for legacy manufacturers—faces a direct and irreversible decline.

This displacement of traditional testing methods is substantiated by recent adoption metrics. According to the American Diabetes Association, in 2024, the usage of continuous glucose monitoring technology reached approximately 47% among youth and 37% among adults with type 1 diabetes in the United States. This substantial migration toward sensor-based solutions indicates that a significant portion of the most intensive users of glucose monitoring are exiting the daily test strip market. Consequently, the widespread acceptance of these advanced devices limits the total addressable market for test strips, effectively counteracting the potential revenue gains that would otherwise result from the increasing global prevalence of diabetes.

Key Market Trends

The Emergence of Value-Based Bundled Diabetes Management Services is fundamentally altering revenue mechanisms, moving away from transactional sales of consumables toward holistic subscription models. Manufacturers are increasingly integrating test strips into comprehensive packages that include remote coaching and data analytics, securing long-term recurring revenue streams less susceptible to price erosion. This strategy enhances patient adherence by shifting focus from isolated testing to continuous care engagement, effectively monetizing outcomes rather than just hardware. The success of this model is evident in the rapid expansion of digital therapeutic platforms; according to DarioHealth, March 2025, in the 'Fourth Quarter and Full Year 2024 Financial and Operating Results', recurring revenues from the B2B2C business channel, which bundles supplies with chronic care management, surged by 398% year-over-year to USD 5.6 million.

Simultaneously, the Proliferation of Private Label and Store-Brand Test Strips is capturing substantial market share as cost containment becomes a priority for payers and consumers. As healthcare systems grapple with the economic burden of diabetes, there is an accelerated shift toward high-quality, lower-cost generic alternatives that displace legacy premium brands in retail settings. This trend drives volume growth for manufacturers specializing in white-label production who offer affordability without compromising accuracy. This segment's robust performance is measurable; according to Sinocare Inc., April 2025, in the '2024 Annual Report', the company, a major producer of cost-effective biosensing technologies, reported a net income of CNY 326.29 million, marking a 14.73% increase compared to the prior year.

Segmental Insights

The gestational diabetes segment represents the fastest-growing category in the global blood glucose test strips market due to the rising incidence of high blood sugar reported during pregnancy. This upward trend is largely influenced by updated protocols from health authorities such as the American Diabetes Association, which advocate for universal screening and strict glucose management to prevent health complications for both mother and child. Consequently, the clinical requirement for frequent self-monitoring to maintain stable glucose levels throughout the day is driving a substantial increase in the demand for test strips.

Regional Insights

North America maintains a leading position in the global blood glucose test strips market, driven by the rising prevalence of diabetes and a highly developed healthcare infrastructure. The market expansion is supported by favorable reimbursement schemes that improve patient affordability and access to daily monitoring tools. Additionally, established guidelines from the American Diabetes Association promote frequent testing, while stringent oversight by the U.S. Food and Drug Administration ensures product reliability. These elements, combined with the strong presence of key manufacturers, secure the region's continued market dominance.

Recent Developments

• In December 2024, Sinocare, a major manufacturer of blood glucose monitoring devices, announced a strategic partnership and exclusive distribution agreement with A. Menarini Diagnostics. This collaboration grants the diagnostics company exclusive rights to register, promote, distribute, and market Sinocare's third-generation continuous glucose monitoring system across more than 20 jurisdictions in Europe. The partnership aims to leverage the distributor's extensive network to introduce the manufacturer's advanced biosensing technology to reimbursed markets, facilitating broader access to accurate glucose monitoring solutions for patients in the region.
• In October 2024, Ascensia Diabetes Care launched the Eversense 365 continuous glucose monitoring system in the United States, following approval from the U.S. Food and Drug Administration. This device is described as the world's first and only one-year CGM system, utilizing a single sensor implanted under the skin to provide long-term monitoring with minimal disruption. The system transmits data to a mobile app, offering users real-time glucose readings and alerts. This launch represents a significant advancement for the company, known for its CONTOUR portfolio of blood glucose monitoring systems, as it addresses the need for longer-lasting sensor technology.
• In September 2024, Trividia Health expanded its portfolio in the global blood glucose market by announcing the launch of the TRUENESS Blood Glucose Monitoring System. This new system was introduced as a low-cost, high-performance solution designed to enhance patient engagement and compliance in diabetes management. The product line features two meter types, including a model that connects via Bluetooth to a mobile application, allowing users to correlate daily activities with their blood glucose results. The launch was positioned to provide accessible, digitally enabled health solutions through retail pharmacies and e-commerce platforms.
• In March 2024, Roche Diabetes Care presented positive study results for a novel continuous glucose monitoring solution at the 17th International Conference on Advanced Technologies and Treatments for Diabetes. The research highlighted the system's predictive algorithms, which are designed to forecast glucose values for up to two hours and indicate the risk of hypoglycemia within the next 30 minutes. The study, involving 48 participants with type 1 or type 2 diabetes, demonstrated high system accuracy with a mean absolute relative deviation of 9.2%. This development aims to empower users with predictive insights to proactively manage their condition and prevent adverse glycemic events.

Key Market Players

• Abbott Laboratories, Inc
• Dexcom, Inc
• F. Hoffmann-La Roche AG
• Medtronic plc
• Ascensia Diabetes Care Holdings AG
• Sinocare Inc
• Nemaura Medical Inc
• Nipro Corporation
• ARKRAY, Inc
• Senseonics Holdings, Inc
• B. Braun Medical Inc
• LifeScan Inc
• Prodigy Diabetes Care LLC

By Type	By End-User	By Region
Thick Film Electrochemical Films Thin Film Electrochemical Films Optical Strips	Hospitals Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Glucose Test Strips Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Glucose Test Strips Market, By Type:

• Thick Film Electrochemical Films
• Thin Film Electrochemical Films
• Optical Strips

• Blood Glucose Test Strips Market, By End-User:

• Hospitals
• Ambulatory Surgical Centers
• Others

• Blood Glucose Test Strips Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE